Previous Study: TRIO025
Next Study: TRIO023

Studies & Results


A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673) Administered to Germline BRCA Mutation Subjects with Locally Advanced and/or Metastatic Breast Cancer

View FDA Study View EU Study


ASCO Annual meeting, 2015

Turner NC, Balmaña J, Fasching PA, et al

A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO).

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at